Glucose-dependent insulinotropic polypeptide suppresses arterial remodeling in mice; Role of a calcium-mediated signaling pathway in vascular endothelial cells Y.Mori
Increasing the cellular populations secreting incretins improves glucose homeostasis and β -cell regeneration M.Terasaki
第78回ADA
Anorexic Peptide Nesfatin-1 Exerts Vasoprotective Effects in injured Artheries of Mice. Y.Mori
Effects of Glucose and Blood Pressure Variability on Oxidative Stress in Type 2 Diabetes with Hypertension. M.Ohara
Actions of Liraglutide on Vascular Endothelial Cells Play a Central Role in the Suppression of Atherosclerosis in Diabetic Mice. M.Hiromura
Vasoprotective Effects of Vildagliptin in Mice Is Masked by Metformin-Overlapping mechanisms Implied. H.Kushima
Liraglutide Suppresses Atherosclerosis via AMP-Activated Protein Kinase Dependent and Independent mechanisms in Diabetic Apolipoprotein E null mice. M.Koshibu
Increased Angiopoietin Like Proteins 4 (ANGPTL4) Is Associated with Higher Concentration of LDL-Triglycerides in Type 2 Diabetes. H.Nagaike
第12回ATTD
EFFECT OF DULAGLUTIDE VERSUS LIRAGLUTIDE ON GLUCOSE VARIABILITY AND OXIDATIVE STRESS AND ENDOTHELIAL FUNCTION IN TYPE 2 DIABETES PATIENTS M. Ohara
Circulating anti-glutamic acid decarboxylase-65 antibody titers are positively associated with the capacity of insulin secretion in acute-onset type 1 diabetes with short duration in a Japanese population.
Yamamura S, Fukui T, Mori Y, Hayashi T, Yamamoto T, Ohara M, Fukase A, Sasamori H, Kobayashi T, Hirano T.
Emphysematous cystitis in an elderly Japanese patient with type 2 diabetes mellitus.Yashima H, Terasaki M, Kushima H, Hirano T. Clin Case Rep. 2019 Feb 6;7(3):585-586. doi: 10.1002/ccr3.2028. eCollection 2019 Mar.
Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms.
Koshibu M, Mori Y, Saito T, Kushima H, Hiromura M, Terasaki M, Takada M, Fukui T, Hirano T. Am J Physiol Endocrinol Metab. 2019 May 1;316(5):E895-E907. doi: 10.1152/ajpendo.00511.2018. Epub 2019 Mar 12
A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic db/db Mice and Type 2 Diabetes Patients.
Terasaki M, Hiromura M, Mori Y, Kohashi K, Kushima H, Koshibu M, Saito T, Yashima H, Watanabe T, Hirano T. Int J Endocrinol. 2018 Dec 9;2018:8458304. doi: 10.1155/2018/8458304. eCollection 2018.
Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study.
Nagaike H, Ohara M, Kohata Y, Hiromura M, Tomoyasu M, Takada M, Yamamoto T, Hayashi T, Fukui T, Hirano T. Diabetes Ther. 2019 Feb;10(1):215-228. doi: 10.1007/s13300-018-0560-8. Epub 2019 Jan 5.
Pheochromocytoma presenting with severe hyperglycemia and metabolic acidosis following intra-articular glucocorticoid administration: a case report.
Tomoyasu M, Mori Y, Fukase A, Kushima H, Hirano T. J Med Case Rep. 2019 Jan 5;13(1):3. doi: 10.1186/s13256-018-1945-z.
Inhibitory effects of vasostatin-1 against atherogenesis.
Sato Y, Watanabe R, Uchiyama N, Ozawa N, Takahashi Y, Shirai R, Sato K, Mori Y, Matsuyama T, Ishibashi-Ueda H, Hirano T, Watanabe T. Clin Sci (Lond). 2018 Dec 5;132(23):2493-2507. doi: 10.1042/CS20180451. Print 2018 Dec 12.
Pathophysiology of Diabetic Dyslipidemia.
Hirano T. J Atheroscler Thromb. 2018 Sep 1;25(9):771-782. doi: 10.5551/jat.RV17023. Epub 2018 Jul 12. Review.
Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice.
Mori Y, Kushima H, Koshibu M, Saito T, Hiromura M, Kohashi K, Terasaki M, Seino Y, Yamada Y, Hirano T. Endocrinology. 2018 Jul 1;159(7):2717-2732. doi: 10.1210/en.2018-00336.
Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation.
Sato K, Yamashita T, Shirai R, Shibata K, Okano T, Yamaguchi M, Mori Y, Hirano T, Watanabe T. Int J Mol Sci. 2018 Apr 26;19(5). pii: E1293. doi: 10.3390/ijms19051293.
Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study.
Yamamoto S, Hayashi T, Ohara M, Goto S, Sato J, Nagaike H, Fukase A, Sato N, Hiromura M, Tomoyasu M, Nakanishi N, Lee S, Osamura A, Yamamoto T, Fukui T, Hirano T. Diabetes Res Clin Pract. 2018 Jun;140:339-346. doi: 10.1016/j.diabres.2018.03.032. Epub 2018 Mar 26.
Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes.
Ohara M, Nagaike H, Goto S, Fukase A, Tanabe Y, Tomoyasu M, Yamamoto T, Hayashi T, Fukui T, Hirano T. Diabetes Res Clin Pract. 2018 May;139:253-261. doi: 10.1016/j.diabres.2018.02.017. Epub 2018 Mar 1.
Analysis of pancreatic volume in acute-onset, slowly-progressive and fulminant type 1 diabetes in a Japanese population.
Sasamori H, Fukui T, Hayashi T, Yamamoto T, Ohara M, Yamamoto S, Kobayashi T, Hirano T. J Diabetes Investig. 2018 Sep;9(5):1091-1099. doi: 10.1111/jdi.12816. Epub 2018 Mar 13.
Diffusion-weighted magnetic resonance imaging in the pancreas of fulminant type 1 diabetes.
Tokunaga A, Imagawa A, Nishio H, Hayata S, Shimomura I, Abiru N, Awata T, Ikegami H, Uchigata Y, Oikawa Y, Osawa H, Kajio H, Kawasaki E, Kawabata Y, Kozawa J, Shimada A, Takahashi K, Tanaka S, Chujo D, Fukui T, Miura J, Yasuda K, Yasuda H, Kobayashi T, Hanafusa T; consultation of Japan Diabetes Society Committee on Fulminant Type 1 Diabetes Mellitus Research. Diabetol Int. 2018 Apr 12;9(4):257-265. doi: 10.1007/s13340-018-0355-1. eCollection 2018 Oct.